Back to Search
Start Over
The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials.
- Source :
-
The British journal of dermatology [Br J Dermatol] 2022 Jun; Vol. 186 (6), pp. 1047-1049. Date of Electronic Publication: 2022 Apr 21. - Publication Year :
- 2022
-
Abstract
- With data from three monotherapy baricitinib phase III randomized clinical trials (RCTs), we conducted a posthoc mediator analysis to assess whether changes in itch or skin severity mediated the treatment effect over placebo on changes in health-related quality of life. In this analysis, baricitinib demonstrated significant improvement in the Dermatology Life Quality Index for which itch mediated approximately half of the changes at weeks 4 and 16.<br /> (© 2022 Eli Lilly and Company. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.)
Details
- Language :
- English
- ISSN :
- 1365-2133
- Volume :
- 186
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- The British journal of dermatology
- Publication Type :
- Report
- Accession number :
- 35041213
- Full Text :
- https://doi.org/10.1111/bjd.21015